Boston Scientific Corporation
BSX
$73.85
-$2.37-3.11%
NYSE
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
EPS (TTM)
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -10.99% | -5.27% | 18.25% | 19.29% | 20.47% |
| Total Depreciation and Amortization | 6.73% | 1.79% | 3.38% | -6.61% | 13.73% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -14.85% | 352.50% | -136.36% | 0.46% | 259.02% |
| Change in Net Operating Assets | 252.27% | -81.12% | 134.37% | -309.26% | 95.18% |
| Cash from Operations | 1.56% | 4.43% | 137.71% | -62.84% | 45.31% |
| Capital Expenditure | -93.92% | -15.29% | 16.04% | 32.49% | -54.75% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 65.23% | 74.63% | -322.18% | 93.01% | -203.28% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -10.77% | -262.50% | 154.05% | -722.22% | 92.56% |
| Cash from Investing | -1.99% | 55.42% | -125.20% | 86.50% | -159.57% |
| Total Debt Issued | -- | -- | -100.00% | 733.16% | -- |
| Total Debt Repaid | 2.79% | 31.53% | 76.05% | -- | -- |
| Issuance of Common Stock | -82.61% | 259.38% | -72.17% | 310.71% | -70.83% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 225.00% | 93.10% | 55.04% | -12,800.00% | 98.88% |
| Cash from Financing | -76.92% | 69.41% | -245.92% | 8.88% | 2,957.14% |
| Foreign Exchange rate Adjustments | 250.00% | -200.00% | -94.87% | 533.33% | -250.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | 0.00% |
| Net Change in Cash | -8.71% | 512.92% | -156.87% | 115.31% | -394.92% |